Endo signs definitive agreement for Paladin Pharma to commercialise Wynzora Cream in Canada

Bristol Myers Squibb's repotrectinib receives positive EU opinion for ROS1-positive NSCLC and NTRK-positive solid tumours

Merck's KEYTRUDA plus chemotherapy receives positive EU opinion for first-line MPM treatment

Sanofi seeks FDA approval for Dupixent in chronic spontaneous urticaria

BioArctic and Eisai report positive European regulatory recommendation for lecanemab marketing authorisation application

Azurity Pharmaceuticals' Danziten granted US FDA approval

PTC Therapeutics' gene therapy to treat AADC deficiency receives US FDA accelerated approval

Caliway Biopharmaceuticals' CBL-514 receives EMA Orphan Drug Designation

Jubilant Radiopharma forms collaboration with Simplified Imaging Solutions

Eupraxia Pharmaceuticals reveals additional data from RESOLVE Phase 1b/2a trial of EP-104GI

ResQ Pharma's LipidRescue Kit receives PDUFA date

Johnson & Johnson's nipocalimab granted US FDA Breakthrough Therapy designation

IDEAYA announces IDE034 as development candidate; Secures global license from Biocytogen

Citius Pharmaceuticals reports promising Phase I trial results for Pembrolizumab and LYMPHIR in cancer treatment

Unicycive Therapeutics' OLC NDA accepted by FDA